美康生物(300439.SZ):新餘醫檢所、鄭州醫檢所通過高新技術企業認定
格隆匯2月9日丨美康生物(300439.SZ)公佈,公司全資孫公司新餘美康盛德醫學檢驗實驗室有限公司(“新餘醫檢所”)、鄭州美康盛德醫學檢驗所有限公司(“鄭州醫檢所”)分別於近日通過了“高新技術企業”認定。
截至公吿出具日,公司及全資子公司寧波美康盛德醫學檢驗所有限公司、寧波美康盛德生物科技有限公司,全資孫公司新餘醫檢所、鄭州醫檢所、杭州美康盛德醫學檢驗實驗室有限公司、深圳美康盛德醫學檢驗實驗室等均被認定為國家高新技術企業。
根據《中華人民共和國企業所得税法》及國家對高新技術企業税收優惠政策的相關規定,上述孫公司自通過高新技術企業認定後,將連續三年享受國家關於高新技術企業的相關優惠政策,即按15%的税率繳納企業所得税。
全資孫公司新餘醫檢所、鄭州醫檢所獲得上述高新技術企業的認定,是對其技術能力的肯定,也是公司綜合實力的體現,有利於進一步提升公司及全資孫公司自主創新能力及綜合競爭力,對公司未來的發展將產生積極作用。上述事項不會對公司當期經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.